A Meta-analysis Of The Risk Of Venous Thrombosis In Patients With Multiple Myeloma Treated With Immunomodulators

Background:Immunomodulators(IMiDs)such as thalidomide,lenalidomide,and pomalidomide are used to treat patients with multiple myeloma(MM),and the prognosis can be greatly improved.Observational studies have shown that the prevention of antithrombotic drugs may reduce the risk of venous thrombosis with IMiDs.Objective:To compare the risk of venous thrombosis in patients with MM treated with IMiDs and non-IMiDs,and to analyze whether prophylactic use of antithrombotic drugs can reduce the risk of venous thrombosis in patients with MM with IMiDs.Results:1.A total of 19 studies that met the inclusion criteria,including 15 thalidomide and 4 lenalidomide 4research of lenalidomide,a total of 6648 patients,a meta-analysis of the risk of venous thrombosis was performed.The total effect of thalidomide or lenalidomide as a basic drug in the treatment of MM patients with venous thrombosis was 1.77(95%CI,1.38,2.27;I2,66.2%;P<0.001);the RR of the thalidomide group was 1.69(95%CI,1.28,2.23;I2,62.2%;P=0.001);lenalidomide group:RR is 1.97(95%CI,1.04,3.78;I2,77.1%;P=0.004),the above results indicate The difference between the venous thrombosis risk in the experimental group(treatment regimen containing IMiDs)and(treatment regimen excluding IMiDs)was statistically significant.The risk of venous thrombosis in patients with MM was 1.11(95%CI,0.90,1.38;I2,89.0%;P<0.001).2.15 studies have complete data on overall response rate(ORR),a total of 5220 patients,thalidomide or lenalidomide as the basic treatment regimen ORR of MM patients:RR 1.40(95%CI,1.04,3.78;I~2,77.1%;P=0.004),the difference between the experimental group and other ORR is statistically significant,the ORR of the experimental group is significantly higher than other indicators.Conclusion:Including treatment with IMiDs can improve the response of patients with MM,but it also increases the risk of venous thrombosis in patients with MM.